Clinical Trials on Posterior Urethral Cancer in Japan

Total 1142 results

Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
ARCAGY/ GINECO GROUP

Recruiting

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1)

Ovarian Cancer

Japan, France
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)

Small Cell Lung Cancer

Taiwan, United States, Hungary, Korea, Republic of, Belgium, United Kingdom, Spain, Brazil, Germany, Poland, Australia, Singapore, Italy, Switzerland, Turkey, Japan, Netherlands, Austria, Greece, Czechia, New Zealand, Russian Federation and more
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

Advanced Breast Cancer

China, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
AbbVie

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, Australia, France, Belgium, China, Austria, United Kingdom, Germany, South Africa, Mexi... and more
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Hungary, Spain, China, Brazil, France, Australia, Czechia, Germany, Israel, Canada, United Kingdom, Japan, Belgium, Romania, Italy, Poland, Lithuania, Korea, Republic of, Bulgaria, Estonia, Russian Federation
Novartis Pharmaceuticals

Withdrawn

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Endometrial Cancer

United States, Russian Federation, Germany, Singapore, Italy, Spain, France, Brazil, Canada, Japan, Poland, Turkey
AstraZeneca

Completed

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

Breast Cancer

United States, Brazil, Czech Republic, France, Hungary, Japan, Belgium, Canada, Netherlands, Italy
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb

Completed

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Gastric Cancer

China, Japan, Korea, Republic of, Taiwan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8)

Colorectal Cancer

United States, Puerto Rico, Canada, Japan, Spain
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
ALX Oncology Inc.
Eli Lilly and Company

Recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Spain, France, Korea, Republic of, Taiwan, United Kingdom, Japan, Singapore, Belgium, Czechia, Italy
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Limited Stage Lung Small Cell Carcinoma | Stage I Lung Cancer AJCC v8

United States, Japan
Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

France, Spain, Australia, United States, Sweden, Belgium, Switzerland, Italy, Egypt, South Africa, Israel, Colombia, Morocco, Norway, Greece, Brazil, Poland, Argentina, Austria, Chile, Czech Republic, Former Yugoslavia, Japan, Lithuania, Macedonia, The Former Yugoslav Republic... and more
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
Novartis Pharmaceuticals

Completed

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Breast Cancer

Canada, Italy, Czechia, United States, Belgium, Austria, Germany, Spain, Japan, Lebanon, Australia, Bulgaria, Israel, Netherlands, Colombia, Hong Kong, Brazil
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia
Bristol-Myers Squibb

Terminated

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W)

Cancer, Hepatocellular

China, United States, Germany, Australia, Italy, Austria, Belgium, Czechia, France, Hong Kong, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Taiwan, Canada
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Daiichi Sankyo, Inc.
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, France, Japan, United Kingdom, Canada
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, Germany, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway, Czechia, Finland, Hong Kong, Netherlands, Poland, Spain, Sweden, Turkey, Denmark, Hungary, Italy, United Kingdom, ... and more
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
AbbVie

Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France, Belgium
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Spain, China, Denmark, Italy, Germany, Mexico, Poland, United States, Brazil, Peru, Thailand, Serbia, Switzerland, Japan, Turkey, Netherlands, Austria, Taiwan, Russian Federation, Ukraine, Greece
GlaxoSmithKline

Active, not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

Neoplasms, Breast

United States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
AbbVie

Terminated

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Cancer | Multiple Myeloma (MM)

United States, Australia, France, Israel, Japan, Spain, Taiwan
AstraZeneca

Recruiting

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Hepatocellular Carcinoma | Biliary Tract Cancer

China, Spain, Korea, Republic of, Italy, United Kingdom, United States, Japan, Taiwan, Hong Kong
National Cancer Institute (NCI)
NRG Oncology

Completed

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States, Korea, Republic of, Japan
Amgen

Recruiting

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

United States, Spain, Austria, Switzerland, United Kingdom, France, Australia, Germany, Japan, Taiwan, Poland, Hong Kong, Netherlands
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Taiwan, Canada, Germany, Argentina, Israel, Korea, Republic of, Denmark, France, India, Chile, Netherlands, Singapore, Japan, Mexico
AstraZeneca

Completed

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)

Locally Advanced Cervical Cancer

United States, Taiwan, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Philippines, Poland, Russian Federation, China, Chile, South Africa
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Belgium, Canada, Australia, Brazil, China, Japan, Taiwan, Israel, France, Singapore, Germany, Italy, Spain, Thailand, Sweden, Turkey, Colombia, Costa Rica, Hong Kong, Poland, Chile, United Kingdom, New... and more
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2)

Non-Small Cell Lung Cancer

United States, Spain, China, Italy, Turkey, Argentina, United Kingdom, Canada, Germany, Brazil, Vietnam, Thailand, Poland, Russian Federation, Japan, Korea, Republic of, Taiwan, Malaysia, Singapore, Romania
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis | Non-Small Cell Lung Cancer

United States, Hong Kong, Spain, Korea, Republic of, China, Israel, Germany, Japan, Singapore, Australia, United Kingdom, Austria, Netherlands, France, Portugal, Sweden, Italy, Belgium
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03)

Gastric Cancer

China, Spain, Korea, Republic of, Canada, Italy, Poland, Japan, United Kingdom, Brazil, Taiwan, United States, Germany, Netherlands, Russian Federation
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

Non-Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Any Solid Tumor

United States, Japan, Taiwan, Australia, Korea, Republic of, Israel, Spain, Switzerland, Singapore, France, Canada, Italy, Germany, United Kingdom, Hong Kong, Denmark
Translational Research Center for Medical Innovation...
Tokyo Medical and Dental University, Japan

Active, not recruiting

International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer (T-REX)

Colon Cancer

Germany, Japan, Taiwan, United Kingdom, Russian Federation, Korea, Republic of, Lithuania
Hoffmann-La Roche

Completed

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Taiho Pharmaceutical Co., Ltd.
TTY Biopharm

Completed

Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer (GEST)

Pancreatic Cancer

Japan, Taiwan
AstraZeneca

Active, not recruiting

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3)

Anticancer Treatment

United States, France, Germany, Spain, Sweden, United Kingdom, Canada, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, China, Taiwan, Hong Kong, Netherlands, Australia, Mexico
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more

Clinical Trials on Posterior Urethral Cancer in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations